Amgen Inc. (LON:0R0T)

Market Cap	117.43B
Revenue (ttm)	26.41B
Net Income (ttm)	4.59B
Shares Out	n/a
EPS (ttm)	8.47
PE Ratio	25.57
Forward PE	14.49
Dividend	7.21 (2.48%)
Ex-Dividend Date	May 16, 2025

Volume	4,289
Average Volume	1,491
Open	279.74
Previous Close	277.47
Day's Range	279.60 - 293.97
52-Week Range	253.20 - 346.67
Beta	n/a
RSI	61.64
Earnings Date	Aug 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 28,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R0T

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD